PolyPid Ltd
NASDAQ:PYPD
PolyPid Ltd
NASDAQ:PYPD
Price:
4.18
USD
-0.24%
Market Cap:
$65.4m
Relative Value
The Relative Value of one
PYPD
stock under the Base Case scenario is
11.45
USD.
Compared to the current market price of 4.18 USD,
PolyPid Ltd
is
Undervalued by 63%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
PYPD
Relative Value
Base Case
11.45
USD
Undervaluation 63%
Multiples Across Competitors
PYPD Competitors Multiples
PolyPid Ltd Competitors
PolyPid Ltd Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| IL |
|
PolyPid Ltd
NASDAQ:PYPD
|
65.4m USD | 0 | -2 | -1.8 | -1.7 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
947B USD | 14.6 | 45.9 | 31 | 33.1 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
584.8B USD | 6.2 | 21.9 | 15.2 | 18.6 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
268.2B CHF | 4.3 | 20.8 | 12.2 | 13.8 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
227.5B GBP | 5.2 | 29.8 | 16.5 | 23.2 | |
| CH |
|
Novartis AG
SIX:NOVN
|
233.8B CHF | 5.4 | 21.6 | 13.4 | 17.2 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
292.5B USD | 4.5 | 16.1 | 10 | 12.2 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD | 94 | -74.6 | 344.9 | 865 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 3.6 | 10.8 | 8 | 9.3 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
152.5B USD | 2.4 | 19.7 | 7.6 | 10.1 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
121.5B USD | 2.5 | 17.2 | 7.2 | 8.9 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
